Jane Street Group LLC acquired a new position in shares of Kura Oncology Inc (NASDAQ:KURA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,628 shares of the company’s stock, valued at approximately $268,000.
A number of other institutional investors have also recently modified their holdings of KURA. DekaBank Deutsche Girozentrale grew its stake in Kura Oncology by 22.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 12,000 shares of the company’s stock worth $235,000 after buying an additional 2,200 shares during the last quarter. Marshall Wace LLP bought a new stake in Kura Oncology during the first quarter worth about $372,000. SG Americas Securities LLC bought a new stake in Kura Oncology during the second quarter worth about $137,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Kura Oncology by 599.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock worth $56,000 after buying an additional 2,420 shares during the last quarter. Finally, Swiss National Bank grew its stake in Kura Oncology by 36.1% during the second quarter. Swiss National Bank now owns 61,400 shares of the company’s stock worth $1,209,000 after buying an additional 16,300 shares during the last quarter. 85.47% of the stock is currently owned by hedge funds and other institutional investors.
KURA opened at $13.84 on Friday. Kura Oncology Inc has a one year low of $10.20 and a one year high of $21.42. The company has a debt-to-equity ratio of 0.03, a current ratio of 23.50 and a quick ratio of 23.50. The company’s 50 day simple moving average is $15.44 and its 200-day simple moving average is $17.02.
KURA has been the topic of several research analyst reports. Wedbush reaffirmed a “positive” rating on shares of Kura Oncology in a research note on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Kura Oncology in a research note on Friday, August 2nd. BidaskClub cut shares of Kura Oncology from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 4th. Deutsche Bank initiated coverage on shares of Kura Oncology in a research note on Thursday, July 18th. They set a “buy” rating and a $28.00 price objective on the stock. Finally, ValuEngine cut shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $27.10.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Article: How to Trade Using Analysts Ratings
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology Inc (NASDAQ:KURA).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.